Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood
Francesco Lo-CocoItalian GIMEMA Cooperative Group

Abstract

After the identification of discrete relapse-risk categories in patients with acute promyelocytic leukemia (APL) receiving all-trans retinoic and idarubicin (AIDA)-like therapies, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) designed a protocol for newly diagnosed APL (AIDA-2000) in which postremission treatment was risk-adapted. Patients with low/intermediate risk received remission at 3 anthracycline-based consolidation courses, whereas high-risk patients received the same schedule as in the previous, non-risk-adapted AIDA-0493 trial including cytarabine. In addition, all patients in the AIDA-2000 received all-trans retinoic acid (ATRA) for 15 days during each consolidation. After induction, 600 of 636 (94.3%) and 420 of 445 (94.4%) patients achieved complete remission in the AIDA-0493 and AIDA-2000, respectively. The 6-year overall survival and cumulative incidence of relapse (CIR) rates were 78.1% versus 87.4% (P = .001) and 27.7% versus 10.7% (P < .0001). Significantly lower CIR rates for patients in the AIDA-2000 were most evident in the high-risk group (49.7% vs 9.3%, respectively, P < .0001). Our data confirm that anthracycline-based consolidation is at least equally effective as cytarabine-containing ...Continue Reading

References

May 9, 2003·Cancer Chemotherapy and Pharmacology·S A Flanagan, K A Meckling
Oct 18, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GhavamzadehN Aghdami
Dec 17, 2008·Hematology·Martin S Tallman, Jessica K Altman
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farhad RavandiHagop Kantarjian
Feb 20, 2009·Proceedings of the National Academy of Sciences of the United States of America·Jiong HuZhu Chen

❮ Previous
Next ❯

Citations

Oct 24, 2012·Annals of Hematology·Eva LengfelderUNKNOWN German Acute Myeloid Leukemia Cooperative Group (AMLCG)
Jan 17, 2013·Current Treatment Options in Oncology·Harry J Iland, John F Seymour
Jun 1, 2006·Current Hematologic Malignancy Reports·Lionel Adès, Pierre Fenaux
Aug 31, 2013·Current Oncology Reports·Miguel A SanzPau Montesinos
Dec 12, 2012·Leukemia·A K BurnettUNKNOWN United Kingdom National Cancer Research Institute Acute Myeloid Leukaemia Subgroup
Jul 12, 2013·The New England Journal of Medicine·Francesco Lo-CocoUNKNOWN Study Alliance Leukemia
Nov 19, 2011·Acta Haematologica·Alessandra MalatoFrancesco Fabbiano
Dec 10, 2013·Hematology·Richard F Schlenk, Hartmut Döhner
Dec 17, 2011·Blood·Jessica K Altman, Martin S Tallman
Apr 25, 2008·Journal of Clinical and Experimental Hematopathology : JCEH·Hiroto NarimatsuIsamu Sugiura
Oct 11, 2012·Revista brasileira de hematologia e hemoterapia·Sarah Cristina Bassi, Eduardo Magalhães Rego
Jan 1, 2014·Current Opinion in Hematology·Harry J IlandAndrew Wei
Sep 17, 2013·International Journal of Hematology·Giuseppina LoglisciMassimo Breccia
Jun 8, 2014·Best Practice & Research. Clinical Haematology·Miguel A SanzPau Montesinos
Jun 8, 2014·Best Practice & Research. Clinical Haematology·Harry J IlandJohn F Seymour
Jun 19, 2014·International Journal of Hematology·Junmin LiZhenyi Wang
Jul 26, 2011·Leukemia & Lymphoma·Annamaria NosariEnrica Morra
Oct 27, 2012·Expert Review of Anticancer Therapy·Riccardo MasettiAndrea Pession
Sep 24, 2013·Expert Review of Anticancer Therapy·Eva LengfelderDaniel Nowak
Aug 2, 2011·Expert Review of Hematology·Massimo Breccia, Giuliana Alimena
Aug 2, 2011·Expert Review of Hematology·Jae H Park, Martin S Tallman
Aug 12, 2014·Blood Reviews·Justin M Watts, Martin S Tallman
Jan 31, 2016·Current Opinion in Hematology·Kelly J Norsworthy, Jessica K Altman
Feb 26, 2014·Seminars in Oncology·Hillard M Lazarus, Paolo F Caimi
Nov 19, 2011·Hematology/oncology Clinics of North America·Muhamed BaljevicMartin S Tallman
Dec 22, 2015·British Journal of Haematology·Francesco Lo-CocoMassimo Breccia
Dec 2, 2015·International Journal of Cardiology·Marco Di PaoloMichele Emdin
Jul 28, 2011·Cancer Science·Tomohiko KamimuraKoichi Akashi
Jul 28, 2012·Cancer Science·Takaaki OnoUNKNOWN Japan Adult Leukemia Study Group
Oct 26, 2011·European Journal of Haematology·Michelle A ElliottMark R Litzow
Oct 15, 2013·British Journal of Haematology·Oussama Abla, Raul C Ribeiro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.